CrataBL, a lectin and Factor Xa inhibitor, plays a role in blood coagulation and impairs thrombus formation

CrataBL, a lectin and Factor Xa inhibitor, plays a role in blood coagulation and impairs thrombus formation

Author Salu, Bruno R. Autor UNIFESP Google Scholar
Ferreira, Rodrigo S. Autor UNIFESP Google Scholar
Brito, Marlon V. Autor UNIFESP Google Scholar
Ottaiano, Tatiana F. Autor UNIFESP Google Scholar
Cruz, Jose Walber M. C. Autor UNIFESP Google Scholar
Silva, Mariana Cristina Cabral Autor UNIFESP Google Scholar
Correia, Maria Tereza S. Google Scholar
Paiva, Patricia M. G. Google Scholar
Maffei, Francisco Humberto de Abreu Google Scholar
Oliva, Maria Luiza Vilela Autor UNIFESP Google Scholar
Institution Universidade de São Paulo (USP)
Hosp Santa Catarina
Universidade Federal de São Paulo (UNIFESP)
Universidade Federal de Pernambuco (UFPE)
Abstract Arterial thrombosis is an important complication of diabetes and cancer, being an important target for therapeutic intervention. Crataeva tapia bark lectin (CrataBL) has been previously shown to have hypoglycemiant effect and also to induce cancer cell apoptosis. It also showed inhibitory activity against Factor Xa (K-iapp = 8.6 m). in the present study, we evaluated the anti-thrombotic properties of CrataBL in arterial thrombosis model. CrataBL prolongs the activated partial thromboplastin time on human and mouse plasma, and it impairs the heparin-induced potentiation of antithrombin III and heparin-induced platelet activation in the presence of low-dose ADP. It is likely that the dense track of positive charge on CrataBL surface competes with the heparin ability to bind to antithrombin III and to stimulate platelets. in the photochemically induced thrombosis model in mice, in the groups treated with 1.25, 5.0, or 10 mg/kg CrataBL, prior to the thrombus induction, the time of total artery occlusion was prolonged by 33.38%, 65%, and 66.11%, respectively, relative to the time of the control group. in contrast to heparin, the bleeding time in CrataBL-treated mice was no longer than in the control. in conclusion, CrataBL was effective in blocking coagulation and arterial thrombus formation, without increasing bleeding time.
Keywords antithrombin III
blood coagulation
Kunitz inhibitor
Language English
Sponsor Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Grant number FAPESP: 2009/53766-5
Date 2014-09-01
Published in Biological Chemistry. Berlin: Walter de Gruyter Gmbh, v. 395, n. 9, p. 1027-1035, 2014.
ISSN 1431-6730 (Sherpa/Romeo, impact factor)
Publisher Walter de Gruyter Gmbh
Extent 1027-1035
Access rights Closed access
Type Article
Web of Science ID WOS:000341864300010

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account